CR20140238A - Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc - Google Patents

Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc

Info

Publication number
CR20140238A
CR20140238A CR20140238A CR20140238A CR20140238A CR 20140238 A CR20140238 A CR 20140238A CR 20140238 A CR20140238 A CR 20140238A CR 20140238 A CR20140238 A CR 20140238A CR 20140238 A CR20140238 A CR 20140238A
Authority
CR
Costa Rica
Prior art keywords
nucleosid
difluoro
inhibitors
derivatives
replacement
Prior art date
Application number
CR20140238A
Other languages
English (en)
Inventor
Jing Zhang
Zhuming Zhang
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of CR20140238A publication Critical patent/CR20140238A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals
    • C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Birds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

La presente exposición se refiere a compuestos de Fórmula I
CR20140238A 2011-12-20 2014-05-21 Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc CR20140238A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161577707P 2011-12-20 2011-12-20

Publications (1)

Publication Number Publication Date
CR20140238A true CR20140238A (es) 2014-06-20

Family

ID=47504913

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140238A CR20140238A (es) 2011-12-20 2014-05-21 Derivados nucleósidos con sustitución 2´, 4´- difluoro-2´-metilo como inhibidores de la replicación del arn del vhc

Country Status (31)

Country Link
US (1) US9108999B2 (es)
EP (1) EP2794629B1 (es)
JP (1) JP5982007B2 (es)
KR (1) KR101765997B1 (es)
CN (1) CN104011061B (es)
AU (1) AU2012357940B2 (es)
BR (1) BR112014013661B1 (es)
CA (1) CA2856179C (es)
CL (1) CL2014001562A1 (es)
CO (1) CO6960551A2 (es)
CR (1) CR20140238A (es)
CY (1) CY1119056T1 (es)
DK (1) DK2794629T3 (es)
EA (1) EA024297B1 (es)
ES (1) ES2636448T3 (es)
HU (1) HUE033727T2 (es)
IL (1) IL232505B (es)
LT (1) LT2794629T (es)
MA (1) MA35750B1 (es)
MX (1) MX350809B (es)
MY (1) MY171577A (es)
PE (1) PE20141423A1 (es)
PH (1) PH12014501134B1 (es)
PL (1) PL2794629T3 (es)
PT (1) PT2794629T (es)
RS (1) RS56212B1 (es)
SG (1) SG11201403364PA (es)
SI (1) SI2794629T1 (es)
UA (1) UA111761C2 (es)
WO (1) WO2013092481A1 (es)
ZA (1) ZA201404273B (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR088441A1 (es) 2011-09-12 2014-06-11 Idenix Pharmaceuticals Inc Compuestos de carboniloximetilfosforamidato sustituido y composiciones farmaceuticas para el tratamiento de infecciones virales
AP3913A (en) 2012-05-22 2016-11-26 Idenix Pharamaceuticals Inc D-amino acid compounds for liver disease
EP2852604B1 (en) 2012-05-22 2017-04-12 Idenix Pharmaceuticals LLC 3',5'-cyclic phosphoramidate prodrugs for hcv infection
US9296778B2 (en) 2012-05-22 2016-03-29 Idenix Pharmaceuticals, Inc. 3′,5′-cyclic phosphate prodrugs for HCV infection
HUE029038T2 (en) 2012-05-25 2017-01-30 Janssen Sciences Ireland Uc Uracil spirooxetan nucleosides
WO2014052638A1 (en) 2012-09-27 2014-04-03 Idenix Pharmaceuticals, Inc. Esters and malonates of sate prodrugs
SG11201502750UA (en) 2012-10-08 2015-06-29 Idenix Pharmaceuticals Inc 2'-chloro nucleoside analogs for hcv infection
EP2935304A1 (en) * 2012-12-19 2015-10-28 IDENIX Pharmaceuticals, Inc. 4'-fluoro nucleosides for the treatment of hcv
US9598457B2 (en) 2012-12-21 2017-03-21 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
GEP201706757B (en) 2012-12-21 2017-10-25 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
US9309275B2 (en) 2013-03-04 2016-04-12 Idenix Pharmaceuticals Llc 3′-deoxy nucleosides for the treatment of HCV
WO2014137930A1 (en) 2013-03-04 2014-09-12 Idenix Pharmaceuticals, Inc. Thiophosphate nucleosides for the treatment of hcv
EP2940031B1 (en) * 2013-03-08 2017-09-27 Nanjing Sanhome Pharmaceutical Co., Ltd. Nucleoside phosphoramidate compounds for use in the treatment of hcv
EP2970357B1 (en) 2013-03-13 2025-01-01 Idenix Pharmaceuticals LLC Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv
EP2981542B1 (en) * 2013-04-01 2021-09-15 Idenix Pharmaceuticals LLC 2',4'-fluoro nucleosides for the treatment of hcv
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
MA46490A1 (fr) * 2013-05-16 2021-04-30 Riboscience Llc Dérivés de nucléosides 4'- fluoro-2' - méthyle substitués
US10005779B2 (en) 2013-06-05 2018-06-26 Idenix Pharmaceuticals Llc 1′,4′-thio nucleosides for the treatment of HCV
WO2015017713A1 (en) * 2013-08-01 2015-02-05 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease
JP6562908B2 (ja) * 2013-10-11 2019-08-21 ヤンセン バイオファーマ インク． 置換ヌクレオシド、置換ヌクレオチドおよびその類似体
WO2015061683A1 (en) * 2013-10-25 2015-04-30 Idenix Pharmaceuticals, Inc. D-amino acid phosphoramidate and d-alanine thiophosphoramidate pronucleotides of nucleoside compounds useful for the treatment of hcv
WO2015161137A1 (en) 2014-04-16 2015-10-22 Idenix Pharmaceuticals, Inc. 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv
HUE051986T2 (hu) 2014-06-24 2021-04-28 Janssen Biopharma Inc Helyettesített nukleozidok, nukleotidek és analógjaik virális fertõzés kezelésére való alkalmazásra
TN2016000566A1 (en) 2014-06-24 2018-04-04 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2016078582A1 (zh) * 2014-11-20 2016-05-26 南京曼杰生物科技有限公司 新型核苷氨基磷酸酯衍生物及其应用
MA41441A (fr) 2014-12-19 2017-12-12 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
MX2018002707A (es) * 2015-09-02 2018-08-01 Abbvie Inc Derivados de tetrahidrofurano antivirales.
EP3455219A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
EP4483875A3 (en) 2016-05-10 2025-04-02 C4 Therapeutics, Inc. Spirocyclic degronimers for target protein degradation
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
CN109641874A (zh) 2016-05-10 2019-04-16 C4医药公司 用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
US10202412B2 (en) 2016-07-08 2019-02-12 Atea Pharmaceuticals, Inc. β-D-2′-deoxy-2′-substituted-4′-substituted-2-substituted-N6-substituted-6-aminopurinenucleotides for the treatment of paramyxovirus and orthomyxovirus infections
WO2018013937A1 (en) 2016-07-14 2018-01-18 Atea Pharmaceuticals, Inc. Beta-d-2'-deoxy-2'-alpha-fluoro-2'-beta-c-substituted-4'-fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
EP3641762B1 (en) 2017-06-20 2026-02-18 C4 Therapeutics, Inc. N/o-linked degrons and degronimers for protein degradation
AU2018335411B2 (en) * 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
IL277160B2 (en) * 2018-03-07 2024-10-01 Univ Emory 4'-halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU498131B2 (en) 1974-02-26 1979-02-15 Ciba-Geigy Ag Production of cephems by cyclization
US4147864A (en) 1975-02-20 1979-04-03 Ciba-Geigy Corporation Process for the manufacture of 7β-amino-3-cephem-3-ol-4 carboxylic acid compounds
US4322347A (en) 1978-04-03 1982-03-30 Bristol-Myers Company 2-Carbamoyloxymethyl-penicillin derivatives
WO1986006380A1 (fr) 1985-04-30 1986-11-06 Takeda Chemical Industries, Ltd. Composes antibacteriens, utilisation et preparation
US5807876A (en) 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
US6054472A (en) 1996-04-23 2000-04-25 Vertex Pharmaceuticals, Incorporated Inhibitors of IMPDH enzyme
CZ298463B6 (cs) 1996-04-23 2007-10-10 Vertex Pharmaceuticals Incorporated Deriváty mocoviny pro použití jako inhibitory IMPDH enzymu a farmaceutické prostredky, které je obsahují
CZ298749B6 (cs) 1996-10-18 2008-01-16 Vertex Pharmaceuticals Incorporated Inhibitory serinových proteáz a farmaceutické prostředky s jejich obsahem
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
AU6701598A (en) 1997-03-14 1998-09-29 Vertex Pharmaceuticals Incorporated Inhibitors of impdh enzyme
US6010848A (en) 1997-07-02 2000-01-04 Smithkline Beecham Corporation Screening methods using an atpase protein from hepatitis C virus
EP1012180B1 (en) 1997-08-11 2004-12-01 Boehringer Ingelheim (Canada) Ltd. Hepatitis c inhibitor peptide analogues
ATE298317T1 (de) 1998-07-27 2005-07-15 Angeletti P Ist Richerche Bio Diketosäure-derivate als hemmstoffe von polymerasen
US6323180B1 (en) 1998-08-10 2001-11-27 Boehringer Ingelheim (Canada) Ltd Hepatitis C inhibitor tri-peptides
ID27787A (id) 1998-08-21 2001-04-26 Viro Pharma Inc Senyawa, komposisi dan metode untuk pengobatan atau pencegahan infeksi yang disebabkan oleh virus dan penyakit-penyakit yang berkaitan
US6440985B1 (en) 1998-09-04 2002-08-27 Viropharma Incorporated Methods for treating viral infections
WO2000018231A1 (en) 1998-09-25 2000-04-06 Viropharma Incorporated Methods for treating or preventing viral infections and associated diseases
SK13332001A3 (sk) 1999-03-19 2002-02-05 Vertex Pharmaceuticals Incorporated Inhibítory IMPDH enzýmu a ich použitie
AU1262001A (en) 1999-11-04 2001-05-14 Biochem Pharma Inc. Method for the treatment or prevention of flaviviridae viral infection using nucleoside analogues
WO2001085172A1 (en) 2000-05-10 2001-11-15 Smithkline Beecham Corporation Novel anti-infectives
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
SV2003000617A (es) 2000-08-31 2003-01-13 Lilly Co Eli Inhibidores de la proteasa peptidomimetica ref. x-14912m
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
US20030170891A1 (en) 2001-06-06 2003-09-11 Mcswiggen James A. RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA)
AU2002344854B2 (en) 2001-06-11 2008-11-06 Vertex Pharmaceuticals (Canada) Incorporated Thiophene derivatives as antiviral agents for flavivirus infection
CA2449999C (en) 2001-06-11 2012-07-31 Shire Biochem Inc. Compounds and methods for the treatment or prevention of flavivirus infections
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
WO2003007945A1 (en) 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP2335700A1 (en) 2001-07-25 2011-06-22 Boehringer Ingelheim (Canada) Ltd. Hepatitis C virus polymerase inhibitors with a heterobicylic structure
JP2005511573A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（５−員）−ヘテロアリールアシルピロリジン誘導体
JP2005511572A (ja) 2001-11-02 2005-04-28 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体
JP2005515172A (ja) 2001-11-02 2005-05-26 グラクソ　グループ　リミテッド Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体
JP2005530843A (ja) 2002-06-21 2005-10-13 メルク　エンド　カムパニー　インコーポレーテッド Ｒｎａ依存性ｒｎａウィルスポリメラーゼ阻害剤としてのヌクレオシド誘導体
AU2003263978A1 (en) * 2002-08-01 2004-02-23 Board Of Trustees Of The Leland Stanford Junior University 2',3'-dideoxynucleoside analogues for the treatment or prevention of flavivitridae infections
US20050020884A1 (en) 2003-02-25 2005-01-27 Hart Charles C. Surgical access system
AU2004233989A1 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
EP1656093A2 (en) 2003-05-14 2006-05-17 Idenix (Cayman) Limited Nucleosides for treatment of infection by corona viruses, toga viruses and picorna viruses
EP1644479A4 (en) 2003-06-16 2008-04-23 Mark W Grinstaff FUNCTIONAL SYNTHETIC MOLECULES AND MACROMOLECULES FOR GENERAL FEEDING
GB0317009D0 (en) 2003-07-21 2003-08-27 Univ Cardiff Chemical compounds
KR20120090077A (ko) 2004-01-30 2012-08-16 얀센 알 앤드 디 아일랜드 Ｈｃｖ ｎｓ?３ 세린 프로테아제 저해제
WO2006063281A2 (en) 2004-12-10 2006-06-15 Emory University 2' and 3' - substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation
JP2009504704A (ja) * 2005-08-15 2009-02-05 エフ．ホフマン−ラ ロシュ アーゲー 抗ウイルス４′−置換プロヌクレオチドホスホルアミダート
US7879815B2 (en) 2006-02-14 2011-02-01 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
GB2442001A (en) 2006-08-11 2008-03-26 Chembiotech Nanoparticle - i-motif nucleic acid bioconjugates
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
JP2010512365A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー ４’−アジドシチジン誘導体の製造方法
US8071568B2 (en) 2007-01-05 2011-12-06 Merck Sharp & Dohme Corp. Nucleoside aryl phosphoramidates for the treatment of RNA-dependent RNA viral infection
US7964580B2 (en) * 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
GB0709791D0 (en) 2007-05-22 2007-06-27 Angeletti P Ist Richerche Bio Antiviral agents
US8173621B2 (en) 2008-06-11 2012-05-08 Gilead Pharmasset Llc Nucleoside cyclicphosphates
WO2011133871A2 (en) 2010-04-22 2011-10-27 Alnylam Pharmaceuticals, Inc. 5'-end derivatives
EA025311B1 (ru) 2010-07-19 2016-12-30 Гайлид Сайэнсиз, Инк. Способы получения диастереомерно чистых фосфорамидатных пролекарств
CA2843885C (en) 2011-08-01 2020-03-10 Mbc Pharma, Inc. Vitamin b6 derivatives of nucleotides, acyclonucleotides and acyclonucleoside phosphonates

Also Published As

Publication number Publication date
NZ625342A (en) 2016-07-29
KR101765997B1 (ko) 2017-08-07
ES2636448T3 (es) 2017-10-05
ZA201404273B (en) 2015-09-30
LT2794629T (lt) 2017-07-25
UA111761C2 (uk) 2016-06-10
PT2794629T (pt) 2017-07-20
CA2856179A1 (en) 2013-06-27
BR112014013661B1 (pt) 2020-10-27
SG11201403364PA (en) 2014-07-30
PH12014501134A1 (en) 2014-07-28
IL232505A0 (en) 2014-06-30
CY1119056T1 (el) 2018-01-10
SI2794629T1 (sl) 2017-10-30
MY171577A (en) 2019-10-21
CO6960551A2 (es) 2014-05-30
PE20141423A1 (es) 2014-10-16
EP2794629A1 (en) 2014-10-29
JP5982007B2 (ja) 2016-08-31
EA201491179A1 (ru) 2014-11-28
US20150004135A1 (en) 2015-01-01
HUE033727T2 (en) 2018-01-29
CA2856179C (en) 2017-02-28
WO2013092481A1 (en) 2013-06-27
BR112014013661A8 (pt) 2017-12-19
AU2012357940A1 (en) 2014-05-29
HK1200836A1 (en) 2015-08-14
PH12014501134B1 (en) 2014-07-28
BR112014013661A2 (pt) 2017-06-13
EP2794629B1 (en) 2017-05-24
CL2014001562A1 (es) 2014-11-14
CN104011061A (zh) 2014-08-27
RS56212B1 (sr) 2017-11-30
MX350809B (es) 2017-09-20
DK2794629T3 (en) 2017-07-24
IL232505B (en) 2019-02-28
JP2015500852A (ja) 2015-01-08
AU2012357940B2 (en) 2017-02-16
EA024297B1 (ru) 2016-09-30
CN104011061B (zh) 2017-06-13
US9108999B2 (en) 2015-08-18
HK1199036A1 (en) 2015-06-19
MA35750B1 (fr) 2014-12-01
MX2014007023A (es) 2014-09-12
KR20140108290A (ko) 2014-09-05
PL2794629T3 (pl) 2018-02-28

Similar Documents

Publication Publication Date Title
CR20140132A (es) Derivados de pirrolopirimidina y purina
UY34523A (es) Derivados de betulina
CR20140166A (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
CO6960551A2 (es) Derivados nucleósidos con sustitución 2,4-difluoro -2-metilo como inhibidores de la replicación del arn del vch
CR20130537A (es) Compuestos heterocíclicos como inhibidores de cinasas
UY34472A (es) Derivados modificados de 4-fenil-piridina
CO6491116A2 (es) Derivados de 5-fluoropirimidinona
UY34092A (es) Nuevos compuestos como inhibidores de jak
CO6831982A2 (es) Pirazolo[4,3-d]pirimidinas útiles como inhibidores de cinasas
UY34051A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CR20140464A (es) Compuestos de heterociclilo
CR20130419A (es) Derivados heterocíclicos de amina
CR20140510A (es) Nucleósidos de espirooxetano de uracilo
CR20130470A (es) INHIBIDORES DE QUINASA RELACIONADOS CON PIRROLO [2,3-d]PIRIMIDINA TROMPOMIOSINA
UA113643C2 (xx) N-цикліламіди як нематоциди
CR20130625A (es) Derivados de la piperidina 3-espirocíclica como agonistas de receptores de la ghrelina
MX378354B (es) Mejoramiento de autofagia o incremento de longevidad por administracion de urolitinas o precursores de las mismas.
ECSP14013251A (es) Derivados de 5-flúor-4-imino-3-(sustituido)-3,4-dihidropirimidin-2(1h)ona
AU2012213775A8 (en) 7-azaindole derivatives
CR20140094A (es) Derivados de etinilo
UY33888A (es) Derivados de (1,2,4) triazolo [4,3-a) quinoxalina como inhibidores de fosfodiesterasas
UY34057A (es) Inhibidores del virus de la hepatitis c
CR20150084A (es) 2-oxo-2,3-dihidro-indoles
CR20140322A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
CR20130475A (es) Derivados de etinilo